Novartis inks agreement to acquire Genoptix
The acquisition will enhance Novartis‘s tools and services that aim to improve health outcomes for patients by advancing the ability to define and monitor individualized treatment programs. Under
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases.
Filed in 2009, the patent will cover inecalcitol doses higher than one milligram (mg) per day until 2029. Currently-marketed vitamin D analogues for indications such as rickets, osteoporosis